Infugem is a drug owned by Sun Pharmaceutical Industries Ltd. It is protected by 1 US drug patent filed in 2018 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 01, 2033. Details of Infugem's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9241948 | Ready to be infused gemcetabine solution |
Jul, 2033
(7 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Infugem's patents.
Latest Legal Activities on Infugem's Patents
Given below is the list of recent legal activities going on the following patents of Infugem.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 26 Jul, 2023 | US9241948 |
| Email Notification | 21 Jan, 2021 | US9241948 |
| Change in Power of Attorney (May Include Associate POA) | 21 Jan, 2021 | US9241948 |
| Correspondence Address Change | 19 Jan, 2021 | US9241948 |
| Correspondence Address Change | 20 Jul, 2020 | US9241948 |
| Email Notification | 05 Feb, 2020 | US9241948 |
| Change in Power of Attorney (May Include Associate POA) | 05 Feb, 2020 | US9241948 |
| Correspondence Address Change | 04 Feb, 2020 | US9241948 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 May, 2019 | US9241948 |
| Patent Issue Date Used in PTA Calculation | 26 Jan, 2016 | US9241948 |
Several oppositions have been filed on Infugem's European patents.
EP oppositions
can significantly impact the timeline for the generic launch of drugs. If an opposition results in the
revocation or
amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an
earlier entry
of generic versions into the market. To help you estimate the potential early arrival of Infugem's generic, the next section provides detailed information on
ongoing and past
EP oppositions related to Infugem patents.
Infugem's Oppositions Filed in EPO
Infugem has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 08, 2016, by Generics (U.K.) Limited. This opposition was filed on patent number EP13165862A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP13165862A | Jan, 2016 | Generics (U.K.) Limited | Patent maintained as amended |
US patents provide insights into the exclusivity only within the United States, but
Infugem is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Infugem's family patents as well as insights into
ongoing legal events
on those patents.
Infugem's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Infugem's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 01, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Infugem Generic API suppliers:
Gemcitabine Hydrochloride is the generic name for the brand Infugem. 25 different companies have already filed for the generic of Infugem, with Shilpa having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Infugem's generic
Alternative Brands for Infugem
There are several other brand drugs using the same active ingredient (Gemcitabine Hydrochloride) as Infugem. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Gemcitabine Hydrochloride, Infugem's active ingredient. Check the complete list of approved generic manufacturers for Infugem
About Infugem
Infugem is a drug owned by Sun Pharmaceutical Industries Ltd. Infugem uses Gemcitabine Hydrochloride as an active ingredient. Infugem was launched by Sun Pharma in 2018.
Approval Date:
Infugem was approved by FDA for market use on 16 July, 2018.
Active Ingredient:
Infugem uses Gemcitabine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Gemcitabine Hydrochloride ingredient
Dosage:
Infugem is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 1600MG BASE/160ML (EQ 10MG BASE/ML) | SOLUTION | Discontinued | INTRAVENOUS |
| EQ 2000MG BASE/200ML (EQ 10MG BASE/ML) | SOLUTION | Discontinued | INTRAVENOUS |
| EQ 1900MG BASE/190ML (EQ 10MG BASE/ML) | SOLUTION | Discontinued | INTRAVENOUS |
| EQ 1700MG BASE/170ML (EQ 10MG BASE/ML) | SOLUTION | Discontinued | INTRAVENOUS |
| EQ 2200MG BASE/220ML (EQ 10MG BASE/ML) | SOLUTION | Discontinued | INTRAVENOUS |
| EQ 1300MG BASE/130ML (EQ 10MG BASE/ML) | SOLUTION | Discontinued | INTRAVENOUS |
| EQ 1200MG BASE/120ML (EQ 10MG BASE/ML) | SOLUTION | Discontinued | INTRAVENOUS |
| EQ 1400MG BASE/140ML (EQ 10MG BASE/ML) | SOLUTION | Discontinued | INTRAVENOUS |
| EQ 1800MG BASE/180ML (EQ 10MG BASE/ML) | SOLUTION | Discontinued | INTRAVENOUS |
| EQ 1500MG BASE/150ML (EQ 10MG BASE/ML) | SOLUTION | Discontinued | INTRAVENOUS |